trending Market Intelligence /marketintelligence/en/news-insights/trending/4JH_ohD3YsJKKzPmNsCrYg2 content esgSubNav
In This List

Strongbridge Biopharma closes share offering

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Strongbridge Biopharma closes share offering

Strongbridge Biopharma plc closed its underwritten public offering of 4 million shares for net proceeds of about $23.4 million.

The company plans to use net proceeds to advance its drug pipeline, including Keveyis to treat primary periodic paralysis and Recorlev to treat Cushing's syndrome, and for other general corporate purposes and general and administrative expenses.

Cantor Fitzgerald & Co. acted as the sole book-running manager and Oppenheimer & Co. Inc. and H.C. Wainwright & Co. LLC acted as co-managers for the offering.